Plain language summary
======================

The supplementation of a hormone called progesterone through intramuscular injections or vaginal administration is well accepted as a method of preventing preterm labor in individuals with specific risk factors. These risk factors include previous preterm births and having a short cervix on ultrasound. There is also emerging evidence suggesting pregnant women on HIV medications may benefit from progesterone supplementation. While this is an accepted intervention, there appears to be an uptake gap in the practice of progesterone supplementation in developing nations. Our study surveyed 147 pregnant Zambian women to understand whether they would find progesterone supplementation acceptable. Our study demonstrated that 94.5% of Zambia women felt that intramuscular or vaginal progesterone supplementations are acceptable interventions for preventing preterm labor. In our sample, 60% of women would prefer intramuscular injections over vaginal administration. This is important data to allow us to feasibly move forward with implementing progesterone supplementation programs in Zambia and other similar developing countries.

Introduction
============

Preterm labor (PTL) is a major contributor to neonatal mortality and morbidity worldwide,[@b1-ijwh-9-827] with low-income countries having disproportionately greater rates[@b2-ijwh-9-827] and more limited resources to manage complications of PTL.[@b3-ijwh-9-827] Many risk factors have been reported for PTL including maternal age, previous PTL, cervical insufficiency, multiple gestations, comorbid maternal conditions (eg, hypertension, diabetes, anemia), and infections.[@b1-ijwh-9-827],[@b4-ijwh-9-827],[@b5-ijwh-9-827]

In individuals at increased risk of PTL, supplemental progesterone is considered a preventative strategy.[@b6-ijwh-9-827],[@b7-ijwh-9-827] The American Committee of Obstetricians and Gynecologists (ACOG)[@b8-ijwh-9-827] and the Society of Obstetricians and Gynecologists of Canada (SOGC)[@b9-ijwh-9-827] guidelines identify previous PTL and short cervix as indications to start supplemental progesterone. Both intramuscular and vaginal preparations of progesterone are acceptable for preventing PTL; there is currently no consensus on either's superiority.[@b8-ijwh-9-827],[@b9-ijwh-9-827]

Pooled analyses and meta-analyses have also demonstrated an association between the use of combination antiretroviral therapy (cART) and PTL and low birth weight (LBW).[@b10-ijwh-9-827],[@b11-ijwh-9-827] Protease inhibitors in particular have been associated with increased risk of PTL.[@b12-ijwh-9-827] Papp et al[@b13-ijwh-9-827] identified an association between protease inhibitor (PI)-based cART and lower progesterone levels. In both humans and mice, lower progesterone levels were correlated with lower fetal/birth weight; and antenatal supplemental progesterone improved fetal weights in pregnant mice.[@b13-ijwh-9-827] These data provide a rationale for progesterone supplementation in pregnant women on PI-based cART.

Existing literature on progesterone acceptability is limited to contraception[@b14-ijwh-9-827],[@b15-ijwh-9-827] and luteal support,[@b16-ijwh-9-827] and generally demonstrate a high degree of acceptability. In a study based in Kenya, Nigeria, and Senegal,[@b14-ijwh-9-827] 98% of women reported satisfaction after 6-month use of a progesterone vaginal ring used for contraceptive benefits. One study[@b16-ijwh-9-827] on luteal support found greater patient satisfaction with vaginal over intramuscular progesterone. In a small qualitative Malawian study of four mothers,[@b17-ijwh-9-827] all were open to intramuscular or vaginal progesterone supplementation to prevent PTL; vaginal administration was preferred due to perceived costs with weekly injections. The study also identified a large knowledge gap regarding the use of supplemental progesterone in the prevention of PTL.

The primary objective of our study was to identify the perceived acceptability of oral, intramuscular, and vaginal progesterone supplementation for preventing PTL and LBW in HIV-infected and HIV-uninfected pregnant Zambian women. The secondary objectives were to identify the level of concern for PTL and LBW in pregnant Zambian women, and the factors that influence the acceptability of progesterone supplementation.

Methods
=======

Study design
------------

The data on acceptability of progesterone supplementation were collected as part of the Progesterone Study in Lusaka, Zambia. The primary aim of the Progesterone Study is to assess the association between maternal serum progesterone levels and birth outcomes in two cohorts of pregnant women: HIV-infected pregnant women on cART, and HIV-uninfected pregnant women. Research ethics board review and approval for this study were received from the University of Zambia in Lusaka, Zambia and from the University Health Network in Toronto, Canada.

All participants provided written informed consent for this study. Data collection from enrolled participants occurred at gestational week (GW) 24--28, GW 35--37, and postpartum. The Baseline Questionnaire ([Appendix 1](https://www.dovepress.com/get_supplementary_file.php?f=Appendix1.pdf)) was administered at GW 24--28, and captured participant data on demographics, past medical and obstetrical history, and social history. At GW 35--37, the Supplemental Progesterone Questionnaire ([Appendix 2](https://www.dovepress.com/get_supplementary_file.php?f=Appendix2.pdf)) captured perception of risk of adverse birth outcomes, past experience with progesterone, and future willingness to take oral, vaginal, or intramuscular progesterone supplementation in the context of preventing future adverse birth outcomes.

Recruitment
-----------

Women were recruited in partnership with the Antenatal Care Program from the Chelstone District Health Centre in Lusaka, Zambia. Using convenience sampling, women who arrived at the health center for prenatal visits were screened by nurses and/or midwives for eligibility. Eligible women were referred to the study nurse for further screening and recruitment. Women were compensated 40 ZMK (\~6 USD) at each visit.

Inclusion criteria: \>18 years of age, pregnant and \<28 weeks gestation, capacity for informed consent, completed HIV testing during pregnancy, willingness to follow-up, and if HIV-positive having a known list of cART medications. Exclusion criteria: current use of supplemental progesterone, on treatment for active tuberculosis or malaria, or on protease inhibitor based cART.

Data collection
---------------

Participant demographics were drawn from responses to the Baseline Questionnaire. The acceptability of progesterone supplementation was assessed using responses to the Supplemental Progesterone Questionnaire, administered at the first follow-up visit. In the event of a premature delivery or a missed visit, the questionnaire was administered postpartum.

All questionnaires were administered by the study nurse in English, Nyanja, or Bemba.

Statistical analysis
--------------------

Sample size calculations were performed for the parent study. The parent study aimed to accrue a sample size of 60 per group to detect a difference of 25% in progesterone levels (based on our in vitro and in vivo studies) between HIV-infected and HIV-uninfected participants with a power of 0.80 and an alpha of 0.05. Categorical variables were analyzed with the Chi square test or Fisher's exact test. Continuous variables were analyzed using Student's *t*-test or Mann--Whitney test as appropriate. A *p*-value of \<0.05 was used as the cutoff for two-sided significance. Statistical analysis was completed on SPSS Statistics Version 21.0 (IBM Corporation, Armonk, NY, USA).

Results
=======

A total of 226 participants were recruited into the study at GW 24--28, of whom 147 presented for a follow-up visit (70 HIV-infected, 77 HIV-uninfected women). Fourteen women presented outside the designated time frame of GW 35--37. Participants lost to follow-up were more likely to be married than those retained in the study; the two groups were otherwise similar.

The demographic data are presented in [Table 1](#t1-ijwh-9-827){ref-type="table"}. HIV-infected women were older (29.9 vs 26.7 years; *p*=0.001) and had a lower education status compared to HIV-uninfected women. Gravidity and parity were also higher in the HIV-infected compared to the HIV-uninfected group (median \[range\] for gravidity: 3 \[1, 8\] vs 2 \[1, 7\]; *p*=0.016; for parity: 2 \[0, 6\] vs 1 \[0, 6\]; *p*=0.008). Household income, history of preterm delivery, and previous progesterone use were similar between groups.

Perceptions of risk associated with PTL and LBW among Zambian women
-------------------------------------------------------------------

One hundred and thirty (88.4%) participants perceived PTL as a serious concern for a newborn's health. HIV-uninfected women were significantly more likely to perceive PTL as a serious health concern for infants compared to HIV-infected women (94.8% vs 81.4%; RR =2.39 \[CI =1.00--5.70\]; *p*=0.011). Further, 39 (26.5%) participants were personally worried about having a preterm delivery. HIV-infected respondents were more likely than HIV-uninfected women to be concerned about PTL in their current pregnancy (34.3% vs 19.5%; RR =1.45 \[CI =1.04--2.01\]; *p*=0.042). Women with previous PTL are not personally more concerned for PTL in their current pregnancy (30.6% vs 25.9%; *p*=0.746) ([Figure 1](#f1-ijwh-9-827){ref-type="fig"}).

General perceptions of the impact of LBW on infant health were not significantly different between HIV-infected and HIV-uninfected women; 113 (76.9%) women believed that LBW is a serious concern for infant health. When asked about their current pregnancy specifically, 36 (24.5%) women were worried that their newborn would be born with LBW.

Acceptability of medication to prevent PTL and LBW
--------------------------------------------------

One of the 147 participants did not complete the questions on the acceptability of medications to prevent PTL and LBW. Of the remaining 146 participants, 144 (98.6%) indicated they would take a medication to prevent PTL and LBW; of note, the two who would not, were HIV-uninfected.

Acceptability of oral formulation of progesterone
-------------------------------------------------

Of the 144 participants willing to take a medication for preventing PTL and LBW, 141 (97.9%) would take the medication orally. One hundred and forty (97.2%) would take the medication daily, and 136 (94.4%) would take the medication from GW 20 to delivery. There was no difference in the acceptability of oral progesterone between the HIV-infected and uninfected groups (*p*=0.347).

Acceptability of intramuscular injections of progesterone
---------------------------------------------------------

Intramuscular injections were acceptable to 120 (83.3%) participants; further, weekly injections were acceptable to 119 (82.6%). One hundred and eighteen (81.9%) participants would be willing to receive this intervention in the clinic, while none were willing to administer intramuscular injections at home. HIV-infected women were more likely to accept intramuscular injections compared to HIV-uninfected women (90.0% vs 77.0%; RR =1.800 \[CI =0.943--3.435\]; *p*=0.037).

Acceptability of vaginal administration of progesterone
-------------------------------------------------------

One hundred and twenty-one (84.0%) participants were willing to use a vaginal formulation. Of these women, 49 (34.0%) were willing to use a vaginal tablet, 58 (40.3%) were willing to use a vaginal gel, and 14 (9.7%) were willing to use either formulations. One hundred and eighteen participants (81.9%) were willing to use the medication (tablet or gel) daily, and 120 participants (83.3%) were willing to use the vaginal medication from GW 20 to delivery. There was a trend toward higher acceptability of vaginal administration in HIV-infected compared to HIV-uninfected women (90.0% vs 78.4%; RR =1.711 \[CI =0.901--3.248\]; *p*=0.057).

The acceptability of the surveyed modes of medication administration is summarized in [Figure 2](#f2-ijwh-9-827){ref-type="fig"}.

Overall preference between intramuscular injections, vaginal tablets, and vaginal gels
--------------------------------------------------------------------------------------

Choosing between the currently recommended formulations to prevent PTL in at-risk women, 89 of 147 participants (60.5%) preferred intramuscular administration, 22 (15.0%) preferred vaginal tablets, and 36 (24.5%) preferred vaginal gels ([Figure 3](#f3-ijwh-9-827){ref-type="fig"}). There was no difference in preference between HIV-infected and HIV-uninfected women (*p*=0.421).

Potential factors affecting progesterone supplementation acceptance
-------------------------------------------------------------------

Participants who had previously used intramuscular progesterone were more likely to prefer intramuscular delivery of progesterone compared to women with no previous experience with intramuscular delivery (74.1% \[40/54\] vs 52.7% \[48/91\]; RR: 1.862 \[CI =1.117--3.104; *p*=0.011\]). Though not reaching significance (*p*=1.000), all women with previous preterm deliveries accepted either intramuscular or vaginal medication to prevent PTL and LBW, as opposed to 93.3% of women with no previous experience with preterm deliveries. HIV-infected (n=70) and HIV-uninfected women (n=77) demonstrated a similar preference for intramuscular or vaginal medication in the prevention of PTL and LBW (65.8% \[46/70\] vs 55.8% \[43/77\]; *p*=0.221).

Overall, 138 of 146 (94.5%) women would be willing to take either an intramuscularly or vaginally delivered medication to prevent PTL and LBW. Only eight women (5.5%) would not consider taking a medication or would only consider an oral medication to prevent PTL/LBW.

Discussion
==========

To our knowledge, this was the largest study to date addressing the attitudes of women in low resource settings toward progesterone supplementation for prevention of PTL and LBW. The results of this study suggest that progesterone supplementation for the prevention of PTL and LBW can be considered an acceptable option in Zambian women. There is a high degree of acceptability (94.5% of participants) for intramuscular or vaginal administrations of progesterone among HIV-infected and HIV-uninfected women. This supports the implementation of ACOG- and SOGC-indications for supplemental progesterone in Zambia.[@b8-ijwh-9-827],[@b9-ijwh-9-827] If the efficacy of progesterone supplementation is demonstrated in cART-associated PTL and LBW, then these results support supplemental intramuscular or vaginal progesterone as an acceptable intervention for HIV-infected Zambian women.

Of the approved delivery modes (ie, excluding oral administration), this study demonstrated a preference for intramuscular administration over vaginal preparations of progesterone. This study contrasts with previous reports[@b16-ijwh-9-827],[@b17-ijwh-9-827] that demonstrated a preference for vaginal administration, one of which included only four mothers and so may not have been representative.[@b17-ijwh-9-827] In an American study completed post-intervention on in vitro fertilization, patients reported higher acceptability for vaginal progesterone due to less discomfort from vaginal administration compared to intramuscular injections.[@b16-ijwh-9-827],[@b17-ijwh-9-827] Since our study was completed prior to intervention, this difference may be attributable to familiarity with intramuscular medications in Zambia. This familiarity hypothesis is supported by a significantly greater preference for intramuscular progesterone over vaginal progesterone in individuals with previous exposure to intramuscular progesterone (eg, Depo-Provera^®^) in our study. Another explanation for the discrepancy may be due to differences in cultural norms and gender roles in developing countries that may affect the uptake of vaginal medications.[@b18-ijwh-9-827]

This study suggests that providing options may improve acceptability of the rollout of a progesterone supplementation program given that 94.5% of women would accept intramuscular or vaginal progesterone. Acceptability decreases to 83%--84% if given only one of the choices. Since there is no superiority demonstrated between vaginal or intramuscular progesterone to prevent PTL, this remains a personal choice for patients.

The acceptability of progesterone supplementation may be driven by a strong perception that PTL and LBW seriously affect infant health. However, fewer women were personally concerned about PTL and LBW. Interestingly, women with a history of PTL (ie, women at high risk for PTL) are not more willing to take medication to prevent PTL and LBW. This knowledge gap regarding risk factors for PTL and LBW has been demonstrated in interviews with patients, community health workers, and clinical officers in Malawi.[@b17-ijwh-9-827] However, due to the limited number of women with previous preterm deliveries (n=13), our study may not be powered to detect a small difference. Despite similar experience with previous PTL, HIV-infected participants were more concerned about PTL for their current pregnancy compared to HIV-uninfected women. This may be because HIV-infected women inherently believe their infection predisposes them to PTL or perhaps, they have been previously counseled regarding their increased risk.

Limitation
==========

There was a high level of attrition in this study (14.4% and 48.5% for the HIV-infected and HIV-uninfected cohorts, respectively). This may be because the study follow-up visit and routine antenatal visits were not coordinated. Retention in the HIV-infected group may be higher because they attend the same clinic for their HIV care, allowing for more opportunities to engage in the study. Furthermore, the closure of the obstetrics ward at the clinic during the study period redirected pregnant women away from the clinic for their deliveries. The loss of participants unable to manage the extra trip to the clinic means the perceptions of women with limited resources may be missed.

All study participants were enrolled in a study to assess normal progesterone levels in pregnant Zambian women, and their attitudes to progesterone supplementation may not reflect those of the general population. However, certain groups of women who have demonstrated willingness for progesterone use (currently using progesterone) or at increased risk of PTL/LBW (currently using PI-based cART)[@b12-ijwh-9-827],[@b13-ijwh-9-827] were excluded from the study, and so we do not think that the acceptability was over-estimated. In addition, since this was a non-interventional study (which allowed women who would as well as those who would not accept treatment to enroll), the acceptability of progesterone supplementation to prevent these complications should reflect the attitudes in the general community of pregnant women.

This study may influence the provision of supplemental progesterone in Zambia and other resource-limited settings. While considered acceptable to HIV-infected women, the efficacy of supplemental progesterone to prevent PTL and LBW in this population remains to be determined. A pilot study of progesterone supplementation in HIV-infected pregnant women is currently underway in Canada.[@b19-ijwh-9-827] At a health systems level, there is a need for cost-benefit analysis of progesterone supplementation in preventing PTL and LBW, and cost-effectiveness analysis of modes of administration.

Conclusion
==========

PTL and LBW are perceived to be serious concerns for infant health among both HIV-infected and HIV-uninfected Zambian women. Over 95% of women surveyed would consider taking medications to prevent PTL and LBW. Oral, intramuscular, and vaginal modes of administration were considered acceptable to the women, with the oral administration being preferred. Between the approved modes of progesterone administration for preventing PTL and LBW, intramuscular administration was preferred, likely due to previous experience with this mode. These data could inform the successful implementation of a progesterone supplementation program to prevent PTL and LBW in Zambia and other similar settings.
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![General and personal concerns for preterm labor (PTL) and low birth weight (LBW) in HIV-infected and HIV-uninfected women.\
**Note:** \*and ^+^indicate a significant difference (*p*\<0.05, chi squared) between HIV-infected and HIV-uninfected women.](ijwh-9-827Fig1){#f1-ijwh-9-827}

![Acceptability of various modes of medication delivery for the prevention of preterm labor and low birth weight.](ijwh-9-827Fig2){#f2-ijwh-9-827}

![Participant preference between the currently recommended modes of progesterone supplementation for the prevention of preterm labor and low birth weight (n=144).](ijwh-9-827Fig3){#f3-ijwh-9-827}

###### 

Demographic features of included sample

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Demographic features                                                          Total participants\   HIV-infected\   HIV-uninfected\   *p*-value[a](#tfn2-ijwh-9-827){ref-type="table-fn"}
                                                                                (n=147)               (n=70)          (n=77)            
  ----------------------------------------------------------------------------- --------------------- --------------- ----------------- -----------------------------------------------------
  Age, mean ± SD                                                                28.3±5.7              29.9±6.04       26.7±4.98         **0.001**

  Gestational age at visit (weeks), mean ± SD                                   36.0±0.73\            36.1±0.70\      36.0±0.77\        0.227
                                                                                (n=130)               (n=60)          (n=70)            

  Monthly household income (ZMW), mean ± SD                                     1,886±2,528\          1,480±1,591\    2,252±3,109\      0.076
                                                                                (n=135)               (n=64)          (n=71)            

  Marital status, n (%)                                                                                                                 0.059

   Single                                                                       30 (20.4)             18 (25.7)       12 (15.6)         

   Married                                                                      113 (76.9)            48 (68.6)       65 (84.4)         

   Divorced                                                                     3 (2.0)               3 (4.3)         0 (0)             

   Windowed                                                                     1 (0.7)               1 (1.4)         0 (0)             

   Separated                                                                    0 (0)                 0 (0)           0 (0)             

  [\^](#tfn1-ijwh-9-827){ref-type="table-fn"}Highest educational level, n (%)                                                           **0.010**

   Less than primary                                                            28 (19.0)             18 (25.7)       10 (13.0)         

   Primary education                                                            59 (40.1)             32 (45.7)       27 (35.1)         

   Secondary education                                                          30 (20.4)             7 (10.0)        23 (29.9)         

   Post-secondary education                                                     29 (19.7)             13 (18.6)       16 (20.8)         

  Gravidity (number of pregnancies), n (%)                                                                                              **0.015**

   1                                                                            40 (27.2)             16 (22.9)       24 (31.2)         

   2                                                                            33 (22.4)             11 (15.7)       22 (28.6)         

   3                                                                            30 (20.4)             16 (22.9)       14 (18.2)         

   4                                                                            27 (18.4)             15 (21.4)       12 (15.6)         

   ≥5                                                                           17 (11.5)             12 (17.1)       5 (6.5)           

  Parity (number of deliveries), n (%)                                                                                                  **0.006**

   0                                                                            43 (29.3)             17 (24.3)       26 (33.8)         

   1                                                                            36 (24.5)             12 (17.1)       24 (31.2)         

   2                                                                            28 (19.0)             15 (21.4)       13 (16.9)         

   3                                                                            26 (17.7)             16 (22.9)       10 (13.0)         

   ≥4                                                                           14 (9.6)              10 (14.2)       4 (5.2)           

  History of previous preterm births, n (%)                                                                                             0.730

   Yes                                                                          13 (8.9)              6 (8.6)         7 (9.1)           

   No                                                                           134 (91.2)            64 (91.4)       70 (90.9)         

  Previous use of progesterone, n (%)                                                                                                   0.623

   No previous use                                                              64 (43.5)             29 (41.4)       35 (45.5)         

   Yes previous use                                                             83 (56.5)             41 (58.6)       42 (54.5)         

  Mode of administration of previous progesterone, n (%)                                                                                

   Oral progesterone[b](#tfn3-ijwh-9-827){ref-type="table-fn"}                  38 (25.9)             19 (24.7)       19 (27.1)         0.931

   Intramuscular progesterone[b](#tfn3-ijwh-9-827){ref-type="table-fn"}         54 (36.7)             24 (34.3)       30 (39.0)         0.210

   Implanted contraceptive device[b](#tfn3-ijwh-9-827){ref-type="table-fn"}     7 (4.8)               5 (7.1)         2 (2.6)           0.336
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

One HIV-uninfected woman did not provide her educational level to the study team.

Comparisons between HIV-infected and HIV-uninfected.

Some women have used multiple forms of progesterone in the past. Hence, the total sum of each form of progesterone does not equal n=83 for total participants, n=41 for HIV-infected, or n=42 for HIV-uninfected. Bold figures indicates *p*\<0.05.
